Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cygnus GlucoWatch G2

This article was originally published in The Gray Sheet

Executive Summary

PMA supplement approval for next-generation glucose monitor system is announced April 2. Enhancements over earlier model include a shorter waiting period between readings, an ability to display and store readings every ten minutes, and an audible alert providing "predictive" notification before a pre-set low glucose level is encountered. U.S. sales of the first-generation system, approved in March 2001, are expected to begin in the next few weeks. Introduction the G2 system will happen later this year...

You may also be interested in...



Cygnus GlucoWatch Biographer For Children To Launch In September

Cygnus plans to offer a pediatric version of its GlucoWatch Biographer for about $700 when shipments begin in late September

Ipsen CEO Outlines Strategy For Long-Term Success

While analysts are struggling to look further than generic competition facing the French firm's best-seller Somatuline, new chief David Loew tells Scrip that intelligent lifecycle management and focused external deals will drive Ipsen's growth.

US Startup Ignites Consumer Health Portfolio Build With North American Rights To ThermaCare

Bridges Consumer Healthcare launched by former Sanofi executives gets its first brand by acquiring North American rights to Pfizer’s ThermaCare HeatWraps brand. Pfizer divested the brand so European regulators would give antitrust clearance to its consumer JV with GSK.

UsernamePublicRestriction

Register

OM006664

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel